Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Open-Label, Multi-Group, Controlled, Randomized Trial of the Safety, Bactericidal Activity, and Pharmacokinetics of TBD09 in Combination With Other Active Agents in Adults With Drug-Sensitive Pulmonary Tuberculosis

NCT07525427 is registered in ClinicalTrials.gov with Gates Medical Research Institute as lead sponsor.

NCT NCT07525427
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07525427 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Open-Label, Multi-Group, Controlled, Randomized Trial of the Safety, Bactericidal Activity, and Pharmacokinetics of TBD09 in Combination With Other Active Agents in Adults With Drug-Sensitive Pulmonary Tuberculosis
Lead sponsor
Gates Medical Research Institute
Phase
Phase 2
Overall status
Recruiting
Start date
April 14, 2026
Completion date
November 5, 2026
Enrollment
150 (estimated)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

drug susceptible pulmonary tuberculosis